Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

<p><strong>Background</strong> Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absenc...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.
Formato:	Journal article
Idioma:	English
Publicado em:	Elsevier 2020

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 t... Por Folegatti, PM, Bittaye, M, Flaxman, A, Lopez, FR, Bellamy, D, Kupke, A, Mair, C, Makinson, R, Sheridan, J, Rohde, C, Halwe, S, Jeong, Y, Park, Y-S, Kim, J-O, Song, M, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshal, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Becker, S, Lambe, T, Hill, A, Ewer, K, Gilbert, S

Publicado em 2020

Journal article

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Registos relacionados